JosephMTuscanoMD

Oncology • Sacramento, CA

Hematologic Oncology

Professor, Internal Medicine, UC, Davis School of Medicine

Join to view full profile

Dr. Tuscano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tuscano's full profile

Already have an account?

Office
4501 X St
Ste 3016
Sacramento, CA 95817
Phone+1 916-734-3772

Fax+1 916-734-7946
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1992 - 1994
University of California Davis HealthResidency, Internal Medicine, 1989 - 1992
Keck School of Medicine of the University of Southern CaliforniaClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2025
MD State Medical License 1992 - 1997
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma Start of enrollment: 2007 Dec 01
Terminated
Phase 1
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Start of enrollment: 2007 Aug 01
Terminated
Phase 3
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2008 Aug 25
Active, not recruiting
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2010 Dec 01
Active, not recruiting
Phase 2
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Start of enrollment: 2012 Apr 16
Completed
Phase 1
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma Start of enrollment: 2013 Jan 14
Completed
Phase 2
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2012 Nov 19
Completed
Phase 1
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia Start of enrollment: 2012 Dec 19
Completed
Phase 2
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2013 Mar 12
Active, not recruiting
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Start of enrollment: 2020 Aug 20
Active, not recruiting
Phase 3
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Start of enrollment: 2021 Feb 24
Recruiting
Phase 2
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Start of enrollment: 2020 Oct 23
Active, not recruiting
Phase 1
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2020 Dec 04
Recruiting
Phase 2
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2024 Sep 03
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Michael Durando, Ajay K Gopal, Joseph Tuscano, Daniel Persky> ;The Oncologist. 2024 Apr 4
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo.
Daniel J Levis, Joshua F Meckler, Robert T O'Donnell, Joseph M Tuscano> ;Current Issues in Molecular Biology. 2023 Aug 25
1 citations
Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.
Tamer Othman, Robert Lowsky, Carol Richman, Rasmus Hoeg, Mehrdad Abedi, Joseph Tuscano> ;Bone Marrow Transplantation. 2023 Oct 1
1 citations
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leuke...
Joshua F Meckler, Daniel J Levis, Daniel P Vang, Joseph M Tuscano> ;Cancer Immunology, Immunotherapy. 2023 Sep 1
2 citations
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell L...
Julio C Chavez, Francine M Foss, Basem M William, Jonathan E Brammer, Sonali M Smith, Anca Prica, Jasmine M Zain, Joseph M Tuscano, Harsh Shah, Neha Mehta-Shah, Pravee...> ;Clinical Cancer Research. 2023 May 15
1 citations
A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML.
Brian A Jonas, Laura A Potter, Joseph M Tuscano, Galkin, M.> ;Leukemia Research Reports. 2023 Jan 1
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse st...
Samantha C Fisch, Joseph M Tuscano, Lihong Qi, Brian A Jonas> ;Leukemia Research. 2022 Nov 1
1 citations
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehen...
Tamer Othman, Benjamin N Moskoff, Gwendolyn Ho, Matthew E Tenold, Tali Azenkot, Margaret L Krackeler, Samantha C Fisch, Laura A Potter, Paul R Kaesberg, Jeanna L Welbo...> ;Leukemia Research. 2022 Aug 1
2 citations
R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Tamer Othman, Juan Penaloza, Shiliang Zhang, Claire E Daniel, Daria Gaut, Caspian Oliai, Elizabeth A Brem, Abinav Baweja, Jane Ly, Jack Reid, Lauren Pinter-Brown, Matt...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
3 citations
Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study.
Christina Poh, John D McPherson, Joseph Tuscano, Qian Li, Arti Parikh-Patel, Christoph F A Vogel, Myles Cockburn, Theresa Keegan> ;BMC Medicine. 2022 Apr 26
4 citations
KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth.
Michiko Shimoda, Yuanzhi Lyu, Kang-Hsin Wang, Ashish Kumar, Hiroki Miura, Joshua F. Meckler, Ryan R. Davis, Chanikarn Chantarasrivong, Chie Izumiya, Clifford G. Tepper...> ;Communications Biology. 2021 Dec 2
77 citations
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo Caimi, Sven de V...> ;Journal of the National Comprehensive Cancer Network. 2021 Nov 1
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas
Tamer Othman, Benjamin N Moskoff, Naseem Esteghamat, Rasmus T. Hoeg, Aaron S. Rosenberg, Brian A. Jonas, Mehrdad Abedi, Carol M. Richman, Joseph Tuscano> ;Leukemia & Lymphoma. 2021 Sep 6
4 citations
Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
Brian Pham, Rasmus T. Hoeg, Rajeev Krishnan, Carol M. Richman, Joseph Tuscano, Mehrdad Abedi> ;Bone Marrow Transplantation. 2021 Sep 1
18 citations
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew ...> ;Haematologica. 2021 Jun 24
1 citations
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refract...
Joseph Tuscano, Christina Poh, Paul Kaesberg, Guilluame Luxardi, Alexander A. Merleev, Alina I. Marusina, Ann Brunson, Aaron S. Rosenberg, Brian A. Jonas, Emanual Mich...> ;Clinical Cancer Research. 2021 Jun 4
30 citations
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center.
Matthew E. Tenold, Benjamin N Moskoff, David J. Benjamin, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph Tuscano, Brian A. Jonas> ;Frontiers in Oncology. 2021 Mar 11
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Matthew E. Tenold, Benjamin N Moskoff, Rajeev Krishnan, Aaron S. Rosenberg, Rasmus T. Hoeg, Mehrdad Abedi, Joseph Tuscano, Brian A. Jonas> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jul 1
5 citations
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Swetha Kambhampati, Bita Fakhri, Weiyun Z. Ai, Lawrence D. Kaplan, Joseph Tuscano, Matthew J. Wieduwilt, Akshay Sudhindra, Erika Cavallone, Jesika Reiner, Charlie Aoun...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Mar 1
4 citations
Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.
Brian A. Jonas, Samantha C Fisch, Aaron S. Rosenberg, Rasmus T. Hoeg, Joseph Tuscano, Mehrdad Abedi> ;American Journal of Hematology. 2021 Apr 1
8 citations
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
Aaron S. Rosenberg, Ann Brunson, Joseph Tuscano, Brian A. Jonas, Rasmus T. Hoeg, Theodore Wun, Theresa H.M. Keegan> ;Blood Cancer Journal. 2021 Jan 7
9 citations
Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia.
Christina Poh, Mili Arora, Sudeep Ghuman, Joseph Tuscano> ;Acta Haematologica. 2021 Jan 1
4 citations
Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
Aaron S. Rosenberg, Thierry Facon, Kejal Parikh, Weiyuan Chung, Shankar Srinivasan, Stanley Kotey, Joseph Tuscano> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 May 1
1 citations
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Joseph Tuscano, Christina Poh, Aaron S. Rosenberg, Brian A. Jonas, Mehrdad Abedi, Gustavo A. Barisone, Emily Schwab, Kathleen Lundeberg, Paul Kaesberg> ;Journal of Hematology. 2020 Aug 13
8 citations
Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies.
Paul Frankel, Vincent Chung, Joseph Tuscano, Tanya Siddiqi, Sagus Sampath, Jeffrey Longmate, Susan Groshen, Edward M. Newman> ;JAMA Network Open. 2020 May 1
Join now to see all

Abstracts/Posters

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed o...
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Washington State Medical Oncology Society (WSMOS) 2013 Spring Oncology Conference
Washington State Medical Oncology Society (WSMOS), Seattle, Washington - 4/19/2013

Press Mentions

Sacramento Woman Celebrates 100th Clinical Trial Dose, Cancer-FreeNovember 15th, 2022
Eighth Annual Crush Challenge Bike Ride to Accelerate Cancer Research on Aug. 27August 5th, 2022
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Join now to see all

Hospital Affiliations

UC Davis Medical CenterSacramento, California
Sacramento Veterans Affairs Medical CenterMather, California